Company Number 05766541
Charity Number 1122484
European Society for Paediatric Endocrinology
Company Limited by Guarantee
Annual Report
31 December 2024

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2024
CONTENTS
PAGE
TRUSTEES ANNUAL REPORT
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY FOR
PAEDIATRIC ENDOCRINOLOGY
10
STATEMENT OF FINANCIAL ACTIVITIES
13
BALANCE SHEET
14
STATEMENT OF CASH FLOWS
15
NOTES TO THE FINANCIAL STATEMENTS
16
MANAGEMENT INFORMATION
25
DETAILED PROFIT AND LOSS ACCOUNT
26

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
The trustees have pleasure in presenting their report and the financial statements of the charitable
company for the year ended 31 December 2024.
REFERENCE AND ADMINISTRATIVE DETAILS
Registered charity name
European Society for Paediatric Endocrinology
Charity registration number
1122484
Company registration number
05766541
Registered office
RIM< Goodman
69 Carter Lane
London
EC4V SEQ
THE TRUSTEES
The trustees who served the charitable company during the year and up to the date of this report were as
follows..
Professor l. Baneriee
Professor S. Cianfarani
Professor M. Cools (Resigned 17 November 2024}
Professor M. Dattani
Professor R. Hamza (Resigned 9 September 2025)
Professor A. Hokken-Koelega (Resigned 9 September 2025)
Professor P. Kuhnen
Professor M. Maghnie
Professor R. Verkauskiene
Dr E. Gevers (Appointed 17 November 2024)
Professor Dr V. lotova (Appointed 9 September 2025)
Auditor
Crowe U.K. LLP
3rd floor
St George's House
56 Peter Street
Manchester
M2 3NQ

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
INTRODUCTION
The European Society for Paediatric Endocrinology ('The Society. and "ESPE.) is a charity and a
company limited by guarantee. Its members are clinicians and researchers with an involvement in
paediatric endocrinology. The Society's beneficiaries are its members, students, paediatric endocrine
patients, and the general public. The Society provides a range of public benefits aimed at providing
educational and research support to these groups and these benefits are detailed in this report.
The principal activity of the Society is to promote knowledge of paediatric endocrinology in the widest
sense to improve patient care., to organise an annual scientific meeting for personal communication and
conferences on subjects of general interest.. and to further research and education in paediatric
endocrinology by bringing together people with an active interest in paediatric endocrinology, by
arranging exchange visits of members and their collaborators, by promoting joint projects and by other
means desired by the Society. The Society also stimulates contacts with other societies with like aims.
PUBLIC BENEFIT
The Society benefits the public through the provision of education, training, guidance and research
evidence to support healthcare professionals to implement the best, eviden￿-led clinical Practi￿ for
paediatric patients, their families and the public more broadly.
Paediatric endocrinology is a specialty of children's medicine (paediatrics) caring for babies, children and
adolescents with growth, puberty, sexual development problems and other disorders of the hormone
producing glands of the body. These include diabetes, thyroid and adrenal gland problems, early and late
puberty, bone conditions and growth hormone deficiency.
Specifically, we provide..
Research funding to support the advancement of scientific and medical research in paediatric
endocrinology
Organised educational and training events for healthcare professionals to ensure the highest
standards in a key area of public health
Support for the publication of an international joumal
The formation of an accessible ne￿Ork of experts in the field of paediatric endocrinology
Clinical guidelines and guidance, patient booklets, summaries and patient-a¢￿sSIb1e documents
This report demonstrates how the Society's charitable funds for the reported year were distributed and
spent, and the benefits and impact of this on the advancement of medical research and clinical practice.
The Society has referred to the Charity Commission's guidance on public benefit when reviewing its aims
and objectives and in planning for future activities. The Trustees confirm that ESPE has complied with its
duty to have regard for the guidance on public benefit published by the Charity Commission on
exercising its powers and duties.
STRUCTURE, GOVERNANCE AND MANAGEMENT
In 1962, following attendance to the 41h Acta Endocrinologica Congress in Geneva, Professor Andrea
Prader invited 26 paediatricians and endocrinologists with an interest in foetal and paediatric issues to
attend an informal post conference meeting and so the first'Paediatric Endocrinology Club, was formed.
These meetings provided young European Investigators with a platform to discuss Paediatric
Endocrinology in-depth. ESPE was officially founded at the meeting in Copenhagen in 1965, with the
mission 'The Society shall promote knowledge of Paediatric Endocrinology in the widest Sense.
The Society is also actively involved in promoting the interests of the general public and in advising on
European health policy in the area of paediatric endocrinology. ESPE is also a founding member of
the I nternational Consortium of Pediatric Endocrinolo
ICPE
which exists to foster global collaboration
in paediatric endocrinology. The European Commission has officially designated ESPE as the body
responsible for organising and monitoring training in paediatn'c endocrinology.
The aims of the Society are as stated in the objectives and activities section. All funds generated are
used to support projects in pursuance of these aims. such as grants to early career scientists,
educational activities, creation and publication of clinical guidelines and guidance, a web site and
newsletter which is available to the public free via the web site as well as being disseminated to

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
members.
In 2006, ESPE transitioned from an unincorporated organisation to a Private Company limited by
guarantee. Registered in England & Wales {Company No". 5766541) and a Registered Charity in 2008
(Charity No.. 1122484).
These accounts have been audited as a charitable organisation.
The Society has the following categories of membership..
1) Clinician Members.. Full,. Early Career, Student or Retired-
2) Scientist Members.. Full, Early Career- Student or Retired-
3) Nurse Members: Full,. Early Career; Student or Retired;
4) Allied Health Professional Members.. Full, Mid-career., Early Career- Student or Retired.
The membership categories were reviewed and restructured in 2021 to provide additional insight into the
members of the Society and to enable future strategic planning. Details of eligibility criteria and fees for
each category are outlined on the Society's website. All applications for membership are reviewed and
approved by the ESPE Council" they are then also presented to the ESPE membership at the next
Annual General Meeting.
ESPE Council is the Society's governing body. ESPE Council consists of not less than eight and not
more than ten members, including the President, the Chairs of the Finance and Strategic Committee,
Chair of the Corporate Liaison Board, Clinical Practice Committee, Programme Organising Committee,
Education and Training Committee, Communication Committee, and Science Committee, and the Annual
Meeting Host. All serve as Directors and Trustees with the exception of the Annual Meeting Host. In
accordance with the ESPE byelaws, Council may appoint up to two more ex officio members provided
the total number on the Council does not exceed ten. Ex-offiGiO Council members have no vote and are
not directors of the Society. Any individual Voting Member who is in good standing with his or her
membership subscription is eligible to stand for election to Council. A Voting Member may nominate
himself or herself.
All members of Council other than the President serve a term of three years. In 2018, the Articles of
Association were changed in relation to Council members, temis of office. Since 2018, the President and
the Chairs of committees have been eligible to extend their first term of office by one year or to stand for
re-election for one further term of three years. If Council members choose to extend their first term of
Offi￿ by one year they are not eligible for re-election for a second term of Offi￿ thereafter. Council
members other than the President and Committee chairs are not eligible for re-election ex￿pt to the
position of President, or as a committee chair.
Since September 2013, the Society has had seven Council Committees, which report to the ESPE
Council through their Chairman. The appointment of the committee chairs and definition of their remit is
the responsibility of ESPE Council. The committees are {1) Strategic and Finance Committee, which is
responsible for the Society's financial planning, budgets, accounts and investments,. (21 Clinical Practice
Committee, which is responsible for undertaking projects to maintain and improve clinical practice
standards in paediatric endocrinology,. (3) Programme Organising Committee, which is responsible for
the scientific programme of the Annual Scientific Meeting., (4) Education and Training Committee, which
is responsible for maintaining and improving education and training for paediatric endocrinologists., (5}
Corporate Liaison Board, which is responsible for establishing and maintaining relationships with industry
representatives,. (6) Communication Committee which is responsible for developing the Society's
communication strategy (7) Science Committee, which is be responsible for scientific collaboration,
scientific networking, ESPE support of projects and the administration of various grants and fellowships,
including the ESPE Research Unit, Research Fellowship, Early Career Scientific Development Grant and
Scientific Career Development Grant, (8) Rare Disease Advisory Committee which reviews the current
activities of ESPE (committee by committee) in the field of rare diseases and identify gaps and overlaps
bet￿een ESPE committees and with other organisations involved in the field of rare diseases and (9)
Policy and Advocacy Committee.
In addition to the Chair, each committee has three or more additional members proposed by the
Committee and approved by Council. In addition to the Council Committees, the Council delegates
certain responsibilities out to other committees or steering groups to organise the following= travel grants.,

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
Clinical Fellowships,. the policy and advocacy program- the rare disease activities- the allocation of prizes
and awards,. ESPE Schools,. the development and update to the training syllabus in paediatric
endocrinology, the editorship of their newsletter and website., and the ESPE Paediatric Endocrinology
Training Centres for Africa (PETCA) programme.
The Society raises its funds mainly through income from its annual scientific meeting and membership
subscriptions. The Society also re￿iVeS some pharmaceutical support through sponsorship of certain
activities. The Society is immensely grateful for this support.
OBJECTIVES AND ACTIVITIES
The objects of the Society are to promote for the public benefit research, education and clinical practice
in paediatric endocrinology by the organisation of conferences, educational activities and publications, by
making grants, by raising public awareness, liaison with national and international legislators, and by any
other appropriate means.
Major areas of activity in support of these objectives
Conferences
The Society runs an annual ESPE Meeting, which normally attracts around 4000 basic scientists and
clinicians from throughout the world. The research and clinical practice presented at the congress aims to
improve scientific research and clinical practice for patients. The ESPE Meeting is recognised worldwide
as a meeting of high scientific and educational quality- It takes place in a different European city each year.
It took Pla￿ in Liverpool in 2024. In addition, every four years ESPE collaborates with the other regional
societies around the world specialising in paediatric endocrinology to contribute to the organisation of the
International Meeting of Paediatric Endocrinology (IMPE), under the banner of the International Consortium
of Paediatric Endocrinology (ICPE). The latest meeting took pla￿ in 2023 in Buenos Aires, Argentina, with
the next meeting scheduled to be held in Japan 2027. In addition, in an effort to work on the continued
care for children from childhood to adulthood, during 2024 the ESPE Annual Meetings was organised as
a joint Congress with the European Society of Endocrinology, taking place in Copenhagen in May 2025.
Education and Trainin
Training in paediatric endocrinology is an important priority for the Society. The Society is officially
designated by the European Commission as the body responsible for organising and monitoring training
in paediatric endocrinology. To this end. numerous educational programmes are sponsored by the Society
in order to offer the most up-t(Fdate and efficient training in paediatric endocrinology.
The Education and Trainin
Committee
ETC
is proactively working to provide structured means of
accreditation for Training Centres in Paediatric Endocrinology in Europe. In addition, electronic education
and training are among the Society's top priorities. The Society has invested in an e-learning web portal,
which gives members and other registrants entran￿ to an interactive learning environment for up-to-date
paediatric endocrinology.
In addition, in 2007 the Society initiated a programme for paediatric training in developing countries
(PETCA), working initially with three paediatric departments in Nairobi, Kenya. Students from a number
of sub-saharan countries continue to graduate from the Nairobi centre and a second PETCA has been
established in Lagos, Nigeria. Graduates from PETCA have now also established the African Society for
Paediatric and Adolescent Endocrinology. ESPE is slowly withdrawing from this project, whilst maintaining
an overview and continuing to provide funding to fellows, to enable the programme to run independently
in the future.
The Society regularly runs six schools which support paediatricians who have entirely or partially
completed their basic paediatric training and who are now either established in, or intending to develop a
deep and continuing interest in, paediatric endocrinology. The Summer, Winter and Diabetes, Obesity and
Metabolism {DOM) schools are designed for those in training who have entirely or partially completed their
paediatric training and who are established in the field or intend to develop their career in paediatric
endocrinology with the DOM School looking at further specialising in diabetes, obesity and metabolism.
The ESPE Maghreb School promotes the training and education of paediatric endocrinologists in French-
speaking North African countries. ESPE also runs a joint academy with the Arab Society for Paediatric

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
Endocrinology and Diabetes which are running successfvlly. A Caucasus and Central Asia School, which
is conducted in both Russian and English, has runs a successful in person event, proactively assessing
the security and safety when near any countries of unrest. The re￿nt school was held in Yerevan,
Armenia.
In addition, the ESPE Connect Webinar Series ran five successfully attended webinars attended by both
ESPE members and non-members. The series aims to deliver very specific content in a webinar format
across a wide-range of topics. The e-learning portal continues to be developed under the remit of the E-
Learning Committee.
A biennial ESPE Science Symposium was initiated in 2017 to help disseminate the latest scientific
knowledge and close the gap between research and patients. The 2025 ESPEIOSCAR Science
Symposium, Mineralization of bone and growth plate, towards the development of new therapies, taking
place in Paris from the 18th and 19th September 2025, was prepared in 2024 and was another highlight of
the ESPE education and training calendar.
Clinical Practice
The Society, through the Clinical Practice Committee (CPC). focuses on the agreement of consensus
statements and the publication of guidelines to guide and standardise the child healthcare system andlor
improve the health of children with endocrine disease in Europe. The CPC is also responsible for ESPE'S
public and patient information and is in the prO￿sS of updating its information leaflets for patients with
endocrine conditions.
Research Unit
Through the Research Unit the Society fosters, facilitates and identifies topics and coordinates high quality
research in the field of paediatric endocrinology in Europe and Mediterranean countries.
Website
The Society runs an active website, which publicises worldwide events in endocrinology and related areas,
and advertises all of the Society's activities. The website has a patient section, where patient booklets
related to common paediatric endocrine conditions can be downloaded in several languages. The website
address is www.euros
e.or
Journal
The Society's official joumal is Hormone Research in Paediatrics, and the goal of its journal is to infomi
readers of the current status of basic and clinical research in the field of endocrinology. The journal is
received by the majority of the members. Abstracts of the studies are available on-line to all.
Newsletter and news alerts
The Society produces a quarterly newsletter. 'ESPE News,. This newsletter ensures that members and
non-members are informed about the Society's latest activities as well as wider updates from the field of
paediatric endocrinology, and is free on-line. In addition. ESPE distributes a monthly electronic news alert,
including forthcoming dates and deadlines as well as Society news. articles from the media on paediatric
endocrinology and information on jobs, grants and prizes as well as the annual meeting. The news alert
is sent to ESPE members and other subscribers.
Su
ort of awards and fellowshi
The Society gives various awards and fellowships supporting its members in their clinical practice and
research. In 2024 there were six awards agreed in recognition of outstanding teaching, research and
contribution to paediatric endocrinology, namely.. the Andrea Prader Prize., the Research Award,. ￿0 ESPE
Young Investigator Awards., the Intemational Outstanding Clinician Award and the ESPE International
Research Award. In addition, the Society offers opportunities for both early career and senior members
who are intent on building up a scientific, research and clinical career in paediatric endocrinology by
providing the following.. ESPE Research Fellowship- ESPE Clinical Fellowship., ESPE Early Career
Scientific Development Grant (formerly the Early Career Scientific Development Award},' Henning
Andersen {meetingl prizes., travel grants, ESPE-Hormone Research in Paediatrics prize- ESPE President's
Poster Awards. The majority of ESPE'S awards are presented during ESPE'S annual meeting. In 2024 the
annual meeting took place in Liverpool and all awards were presented during the meeting.

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
Volunteers
The Society's success depends on the time and commitment devoted to it by a body of volunteers, who
assist on committees, editorial boards, programme development for meetings, as speakers and chairs,
local congress organisation and other activities. The Society is immensely grateful to all these volunteers
for their hard work.
A volunteer recruitment drive was organised during the 2023 Annual Meeting resulting in around 40
applications of ESPE members to support various activities and initiatives- the initiative continued to take
pla￿ in 2024 in which different volunteer task forces were established.. membership group., snippets.,
review of ESPE Syllabus; Science Committee Survey.
Financial review
The Society has resulted net outgoing resources for the year of É148,097 (2023.. net incoming resources
ofÉ270,048}.
Reserve fund policy
Income to the Society is mainly generated through membership. the annual scientific meeting, industry
support and investment income.
The reserve policy tskes into consideration the major risks that could fa￿ the Society as detailed in the
Society's Risk Register, which was developed in 2018 and is reviewed by Council four times a year. The
principle risks are assessed in terms of their significance and probability and given a red, amber or green
rating according to their potential impact on the Society- These are listed below, along with their impact
rating.
(1) Significant loss of pharmaceutical sponsorship. Industry fvnding is currently provided for ESPE'S
annual meeting and many of its Society activities (RED)-
(2) Loss of pharma￿Utical sponsorship due to companies without long-acting growth hormone products
(AMBER}
(3) Securing the relevance and longevity of the Society (GREEN).
(4) Cessation of key suppliers (GREEN).
(5) Loss of leadership (GREEN).
(6) Conflict of interest of Council members and other stakeholders affecting key decisions and lack of
trust in governance (GREEN).
(7) Impact of Brexit {GREEN)
(8) Relationship with Karger (GREEN).
(9) Long-term financial Un￿rtaInty beyond ESPE'S budgeting period due to the changing future outlook
of scientific associations. (AMBER).
(10) Lack of awareness by the public of ESPE and paediatric endocrinology through the absence of
activity in advocacy and public awareness activities (AMBER).
(11) Financial instability due to global events affecting Society's long-term ability to deliver its charitable
activities. (AMBER)
(12) Cyber security of ESPE website and potential breach of member data. (RED)
(13) Lack of relationship with advocacy groups. (AMBER)
(14) Financial instability due to global events affecting Society's long-term ability to deliver its charitable
activities. (AMBER)

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
This reserve policy is designed to allow the Society to continue running its activities for a Iwo-year period,
at its current level, after which the projects would be reevaluated depending on the level of success in
generating new revenue streams. Alowing for a two-year period of financial difficulty would also help to
minimize the risk of compromising the objectives and core activities of the Society- A reduction in the
scale of activities has been assumed, but not large-scale cancellation of projects. It has been assumed
that membership income will drop slightiy but remain fairty consistent
Conclusion
Using calculations based on the summary above, the Trustees of the Society consider that the required
level of readily useable reseNes should be É2,400,000. The current Society unrestricted reserve is
5,725,925 as of 31 December 2024 and so the Society has É3,325,925 as at 31 December 2024 at its
disposal to use towards its charitable objectives.
A reserve at this level will provide the security required for ESPE to continue to fulfil its charitable objectives
even if its income is reduced.
ACHIEVEMENTS AND PERFORMANCE
Conferences
In 2024 ESPE'S annual scientific meeting was held in Liverpool, UK and had 2,231 paid in-person
registrations of which 731 are ESPE members. There were 281 in-person and on-demand tickets for non-
members, totalling 2,512 meeting attendees which was greatly su￿sSfUl.
Education in Develo
Countries
ESPE continued to support education of paediatric endocrinology in developing countries, through-
supporting the PETCA project
delivering the ESPE Winter. Summer and DOM School in person to enable aC￿sS to high quality
teaching
delivering Caucasus & Central Asia School in person
running the ESPE Clinical Fellowship for fellows from developing countries to gain aC￿sS to high
quality educational experien￿ in top European centres for 34 months
provision of multilingual facilities on the e-Learning portal
provision of patient information leaflets for common paediatric endocrine disorders in multiple
languages
Grants Fellowshi
s Scholarshi
s and Awards
In 2024, ESPE grant, fellowship and awards funding totalled E440 000 the funding was back to pre-
pandemic levels. One Visiting Professorship. under the Science Committee, was given in 2024.
Additionally, ESPE has provided 40 Travel Grants for participants at ESPE'S Annual Meeting.
Science
The Science Committee, which oversees ESPE'S suite ofgrants, carried out its activities as normal in 2024
and was able to manage the process of and award all its grants as normal.
In 2024, ESPE awarded the following grants-.
Clinical Fellowship Grant- 21 awardees.
Research Fellowship Grant- 1 awardee,
Early Career Scientific Development Grant- 2 awardees.
Research Unit Grant- 1 awardee and its team.
Website
The ESPE website provides an important tool to inform paediatric endocrinologists about the activities of
the Society and this is supplemented by other communications tools as detailed below, driving traffic
towards the central ESPE website. The ESPE website was rebuilt and redesigned by Health-E Solutions
and a website working group, using a WordPress plaffomi. The website was launched in De￿mber 2022.

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
Communications
ESPE continues to communicate to its members through multiple channels, including the quarterly digital
magazine ESPE News, monthly email newsletter, quarterly AfFiliate Society email newsletters, dedicated
email messaging, the website, and social media, including Facebook, X, and Linkedln.
ESPE increased the number of followers across all social media channels, most notably we saw a 64.3 %
increase on Linkedln. We also re￿iVed 286,860 impressions across all channels an increase of nearly
40,000 {39,952) on 2023.
During 2024, ESPE decreased the amount of emails sent by 36 % (compared to the previous year), to be
more tactful with what was sent and to avoid bombarding audiences. The open and click through rates
rose by over 20 % and over 30 % respectively. ESPE'S open and click rates are ex￿lIent - on average
across all industries in 2024 the average open rate was 35.6 % (ESPE'S is 42.5 % ) and the average click
through rate was 2.6 % (ESPE'S is 30.3 % ), so the audience is very clearly engaged and this is an excellent
channel to disseminate information through.
ESPE did a considerable amount of work to streamline the website. condense webpages, and make the
site more user friendly, and this is still ongoing. In 2024 there was an increased number of website users,
but a decline in other metrics. Reduced engagement time could be because the information people are
looking for is easier to find so users do not need to stay on the website as long. Also the amount of pages
has been reduced, therefore there are physically less pages for people to view.
Journal
The official ESPE journal continues to be Hormone Research in Paediatrics. Karger continues to publish
the journal and supports two Hormone Research in Paediatrics prizes. These are awarded at the annual
conference.
Membershi
478 new membership applications were received in 2024, all of which were approved by Council.
Membership totalled 1,429 which was 15 members more than the previous year with a contributing steady
number of members.
International collaboration
ESPE continues to be part of the International Consortium of Paediatric Endocrinology {ICPE) and is
represented at its meetings by the President and Treasurer. This virtual ne￿Ork involves reference centres
across Europe and aims to tackle complex or rare endocrine conditions that require highly specialised
treatment and a concentration of knowledge and resources. In response to the crisis in Ukraine, ESPE
provided free membership to Ukrainian members and free registration and online access to ESPE 2024.
Or
anisation
ESPE contracted a new association management company to work with from December 2022 onwards,
MCI UK. In 2024 onwards. the association management company MCI Brussels took over the association
management, keeping important elements of the team of MCI UK. The current contract sits with MCI
Brussels will provide the secretsriat and association management services, with Bioscientifica continuing
the professional congress organisation. The role of Senior Operating Officer is provided by MCI Brussels,
to Co-ordinate all activities and provide additional strategic support to ESPE Council.
PLANS FOR FUTURE PERIODS
In 2024 ESPE will focus on continuing to deliver online content via the schools and webinar series. In
addition the annual scientific meeting will take pla￿ in Copenhagen. jointly with ESE, and in 2026 in
Marseille.
ESPE'S strategic planning will continue with an annual Council meeting held specifically to address
strategic issues.
ESPE will continue to support science and research in the field with its grants and fellowships.

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
RESPONSIBILITIES OF THE TRUSTEES
The trustees are responsible for preparing the Trustees Annual Report and the financial statements in
accordance with applicable law and regulations.
Company law requires the trustees to prepare financial statements for each financial year. Under that law
the trustees have elected to prepare the financial statements in accordance with United Kingdom Generally
Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under
company law the trustees must not approve the financial statements unless they are satisfied that they
give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for
that period.
In preparing these financial statements, the trustees are required to=
select suitable accounting policies and then apply them consistently.,
make judgements and estimates that are reasonable and prudent..
prepare the financial statements on the going con￿rn basis unless it is inappropriate to presume
that the charity will continue in operation.
The trustees are responsible for keeping proper accounting records which disclose with reasonable
accuracy at any time the financial position of the charity and which enable them to ensure that the financial
statements comply with Companies Act 2006. The trustees are also responsible for safeguarding the
assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and
other irregularities.
The trustees are also responsible for the maintenance and integrity of the information included on the
charity's website. Legislation in the United Kingdom goveming the preparation and dissemination of
financial statements may differ from legislation in other jurisdictions.
In so far as the trustees are aware"
there is no relevant audit information of which the charity's auditor is unaware,. and
the trustees have taken all steps that they ought to have taken to make themselves aware of any
relevant audit information and to establish that the auditor is aware of that information.
AUDITOR
A resolution to formally appoint Crowe U.K. LLP as auditorforthe ensuing year was approved by members
at the 2019 Annual General Meeting.
SMALL COMPANY PROVISIONS
This report has been prepared in accordan￿ with the special provisions for small companies under Part
15 of the Companies Act 2006.
Registered office..
RWK Goodman
69 Carter Lane
London
EC4V SEQ
Signed on behalf of the trustees
on
18 JAN 2026
Professor Rasa Verkauskiene
Treasurer. ESPE
Docusloned by".
A824891811B54¢D...

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY FOR
PAEDIATRIC ENDOCRINOLOGY
Opinion
We have audited the financial statements of European Society for Paediatric Endocrinology ('the charitable
company,) for the year ended 31 December 2024 which comprise the Statement of Financial Activities,
Balance Sheet and Statement of Cash Flows and notes to the financial statements, including significant
accounting policies. The financial reporting framework that has been applied in their preparation is
applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102
The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally
Accepted Accounting Practice).
In our opinion the financial statements=
give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and
of its income and expenditure for the year then ended;
have been properly prepared in accordan￿ with United Kingdom Generally Accepted Accounting
practi￿., and
have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAS {UK)) and
applicable law. Our responsibilities under those standards are further described in the Auditorfs
responsibilities for the audit of the financial statements section of our report. We are independent of the
charitable company in accordance with the ethical requirements that are relevant to our audit of the
financial statements in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical
responsibilities in accordance with these requirements. We believe that the audit eviden￿ we have
obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustee's use of the going concern basis
of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events
or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability
to continue as a going concem for a period of at least ￿e1ve months from when the financial statements
are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in
the relevant sections of this report.
Other infomiation
The trustees are responsible for the other information contained within the annual report. The other
information comprises the information included in the annual report, other than the financial statements
and our auditor's report thereon. Our opinion on the financial statements does not cover the other
information and, ex￿pt to the extent otherwise explicitly stated in our report, we do not express any form
of assurance conclusion thereon.
Our responsibility is to read the other infomiation and, in doing so, consider whether the other information
is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise
appears to be materially misstated. If we identify such material inconsistencies or apparent material
misstatements, we are required to determine whether this gives rise to a material misstatement in the
financial statements themselves. If, based on the work we have performed, we conclude that there is a
material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
10

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY FOR
PAEDIATRIC ENDOCRINOLOGY
Opinions on other matters prescribed by the Companies Act 2006
In our opinion based on the work undertaken in the course of our audit
the information given in the trustees, report. which includes the directors, report prepared for the
purposes of company law, for the financial year for which the financial statements are prepared is
consistent with the financial statements- and
the directors, report included within the trustees, report have been prepared in accordance with
applicable legal requirements.
Matters on which we are required to report by exception
In light of the knowledge and understanding of the charitable company and their environment obtained in
the course of the audit, we have not identified material misstatements in the directors, report included
within the trustees, report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006
requires us to report to you if, in our opinion=
adequate and proper accounting records have not been kept" or
the financial statements are not in agreement with the accounting records and returns,. or
rtain disclosures of trustees, remuneration specified by law are not made,. or
we have not received all the information and explanations we require for our audit- or
the trustees were not entitled to prepare the financial statements in accordance with the small
companies, regime and take advantage of the small companies, exemptions in preparing the trustees,
directors, report and from the requirement to prepare a strategic report.
Responsibilities of trustees
As explained more fully in the trustees. responsibilities statement set out on page 9, the trustees (who are
also the directors of the charitable company for the purposes of company lawl are responsible for the
preparation of the financial statements and for being satisfied that they give a true and fair view, and for
such internal control as the trustees determine is ne￿SSary to enable the preparation of financial
statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the trustees are responsible for assessing the charitable company's
ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using
the going concern basis of accounting unless the trustees either intend to liquidate the charitable company
or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assuran￿ about whether the financial statements as a whole are
free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes
our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit
conducted in accordance with ISAS {UKI will always detect a material misstatement when it exists.
Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate,
they could reasonably be expected to influence the economic decisions of users taken on the basis of
these financial statements.
Details of the extent to which the audit was considered capable of detecting irregularities, including fraud
and non-compliance with laws and regulations are set out below.
A further description of our responsibilities for the audit of the financial statements is located on the
Financial Reporting Council's website at.. www.frc.or
. uklauditorsres
onsibilities. This description forms
part of our auditor's report.
Extent to which the audit was considered capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified
and assessed the risks of material misstatement of the financial statements from irregularities, whether

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY FOR
PAEDIATRIC ENDOCRINOLOGY
due to fraud or error, and discussed these between our audit team members. We then designed and
performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and
appropriate to provide a basis for our opinion.
We obtained an understanding of the legal and regulatory frameworks within which the charitable company
operates, focusing on those laws and regulations that have a direct effect on the determination of material
amounts and disclosures in the financial statements. The laws and regulations we considered in this
context were the Companies Act 2006 together with the Charities SORP (FRS102} 2019. We assessed
the required compliance with these laws and regulations as part of our audit procedures on the related
financial statement items.
In addition, we considered provisions of other laws and regulations that do not have a direct effect on the
financial statements but compliance with which might be fundamental to the charitable company's ability
to operate or to avoid a material penalty. We also considered the opportunities and in￿ntiveS that may
exist within the charitable company for fraud. The laws and regulations we considered in this context for
the UK operations were Charity Commission Regulations. Auditing standards limit the required audit
procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other
management and inspection of regulatory and legal correspondence. if any.
We identified the greatest risk of material impact on the financial statements from irregularities, including
fraud, to be within the recognition of granucontract income and the override of controls by management.
Our audit procedures to respond to these risks included vouching a sample of receipts in the year to signed
agreements and to bank statements, enquiries of management and the Trustees about their own
identification and assessment of the risks of irregularities, sample testing on the posting of journals,
reviewing accounting estimates for biases, and reading regulatory correspondence with the Charity
Commission and minutes of governance meetings.
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected
some material misstatements in the financial statements, even though we have properly planned and
performed our audit in accordance with auditing standards. For example, the further removed non-
compliance with laws and regulations (irregularities) is from the events and transactions reflected in the
financial statements, the less likely the inherently limited procedures required by auditing standards would
identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as
these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal
controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-
compliance with all laws and regulations.
Use of our report
This report is made solely to the charitable company's members, as a body. in accordance with Chapter 3
of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the
charitable company's members those matters we are required to state to them in an auditor's report and
for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to
anyone other than the charitable company and the charitable company's members as a body, for our audit
work, for this report, or for the opinions we have formed.
Vicky Szulist
Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
statutory Auditor
3rd Floor, St George's House
56 Peter Street
Manchester
M2 3NQ
Date.. 21st January 2026
12

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNTI
YEAR ENDED 31 DECEMBER 2024
Restricted Unrestricted
Funds
Funds Total Funds
2024
2024
2024
Total Funds
2023
Notes
INCOME AND ENDOWMENTS
FROM:
Charitable activities
Investments
Other trading activities
159,512
3,371,918
30,521
140,357
3,531,430
30,521
140,357
3,322,632
202,498
TOTAL INCOMING
RESOURCES
159.512
3.542.796
3,702,308
3,525,130
EXPENDITURE ON:
Charitable activities
(408.551) (3,441.854) (3.850,405) (3,255,082)
TOTAL RESOURCES
EXPENDED
(408,551) (3,441.854) (3.850,405) (3,255,082)
NET (EXPENDITURE)IINCOME
FOR THE YEAR BEFORE
TRANSFERS
Transfers be￿een funds
(249,039)
213,463
100,942
(213,463)
(148,097)
270,048
14
NET MOVEMENT IN FUNDS
135,576) (112,521) (148,097)
270,048
RECONCILIATION OF FUNDS:
Total funds brought forward
83.982
5,908,446
5,992,428
5,722,380
TOTAL FUNDS CARRIED
FORWARD
48,406
5,795,925
5,844,331
5,992,428
The Statement of Financial Activities includes all gains and losses recognised in the year.
l incoming resources and resources expended derive from continuing activities.
The notes on pages 16 to 24 form part of these financial statements.
13

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
YEAR ENDED 31 DECEMBER 2024
2024
2023
NOTE
FIXED ASSETS
Investment in Joint venture
11
60
CURRENT ASSETS
Debtors
Cash at bank
12
911.242
5.743.685
6,654,927
1.218.477
5.334,119
6,552,596
CREDITORS: Amounts falling due
within one year
13
(810.656)
(560,168)
NET CURRENT ASSETS
5.844.271
5,992,428
TOTAL ASSETS LESS CURRENT
LIABILITIES
5.844.331
5,992,428
NET ASSETS
5.844.331
5.992,428
FUNDS
Unrestricted income funds
Restricted funds
14
14
5.795.925
48,406
5,908,446
83,982
TOTAL FUNDS
5,844,331
5,992,428
These financial statements have been prepared in accordance with the special provisions for small
companies under Part 15 of the Companies Act 2006.
These financial ststements were approved and authorised for issue by the members of the committee on
18 January 2026 and are signed on their behalf by:
Professor Rasa Verkauskiene
Treasurer, ESPE
IASA VLyLAws&
A824891811854C£&...
Company Registration Number: 05766541
The notes on pages 16 to 24 form part of these financial statements.
14

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
STATEMENT OF CASH FLOWS
YEAR ENDED 31 DECEMBER 2024
2024
2023
Cash flows from operating activities
17
409,626
(258,147)
Cash flows from investing activities
18
(60)
Change in cash in the year
409,566
(258,147)
Cash at the beginning of the year
5,334,119
5,592,266
Cash at the end of the year
5,743,685
5,334,119
Analysis of net debt
At 1 January
2024
Cashflow
At 31 December
2024
Cash in hand, at bank
5.334,119
409,566
5,743,685
5,334,119
409,566
5,743,685
The notes on pages 16 to 24 forn) part of these financial statements.
15

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2024
ACCOUNTING POLICIES
Charitable company information
The European Society of Paediatric Endocrinology is a private limited charitable company, limited
by guarantee by not having any share capital, incorporated and domiciled in England and Wales.
The registered office is RVVK Goodman, 69 Carter Lane, London, EC4V SEQ.
Basis of accounting
The financial statements have been prepared under the historical cost convention and in
accordance with the Statement of Recommended Practi￿.. Accounting and Reporting by Charities
preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK
and Republic of Ireland {FRS 102) (effective 1 January 2015), the Charities Act 2011 and the
Companies Act 2006.
The company constitutes a public benefit entity as defined by FRS 102.
Going concern
The Trustees have undertaken detailed planning and forecasting work, in order to ensure that the
charity's financial resources and contingency planning are sufficientto allow the Charity to continue
as a going concern for the foreseeable future, being at least ￿e1ve months from the date of
approval of these financial statements. The Trustees have therefore prepared the financial
statements on a going concern basis. With the help of the strategic and finance committee, the
Trustees have undertaken detailed planning for future annual meetings beyond the next 12
months, including the 2025 annual meeting to be held in Copenhagen.
In addition to the annual meeting, the society continues to maintain contact with its members
through different activities including the award of fellowships and grants, the organisation of
specialist events, and online teaching activities.
The preparation of the financial statements in Complian￿ with FRS 102 requires the use of certain
critical accounting estimates. It also requires management to exercise judgement in applying the
Charitable Company's accounting policies (see note 2).
Incoming resources
Sponsorships, membership subscriptions and investment income are accounted for on an accruals
basis.
Resources expended
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation
committing the charity to that expenditure. it is probable that settlement will be required and the
amount of the obligation can be measured reliably.
All expenditure is accounted for on an accruals basis. All expenses including support costs and
governance costs are allocated or apportioned to the applicable expenditure headings.
Support costs are allocated to expenses where they are incurred in direct relation to the expense,
elsewhere they are allocated on a per￿ntage of overall expenses incurred.
16

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
ACCOUNTING POLICIES (continued
Governance costs include those costs incurred in the governance of the charity. These costs
include costs related to statutory audit together with legal and professional fees and the costs of
trustee meetings.
Foreign currencies
The company's functional and presentational currency is Euros. The exchange rate be￿een
sterling and the Euro at 31 December 2024 was £1: É1.20.
Assets and liabilities in foreign currencies are translated into Euros at the rates of exchange ruling
at the balance sheet date. Transactions in foreign currencies are translated into Euros at the rate
of exchange ruling at the date of the transaction. Exchange differences are taken into account in
arriving at the net incoming resources for the year.
Financial instruments
The company only has financial assets and liabilities of a kind that qualify as basic financial
instruments. Basic financial instruments are initially recognised at transaction value and
subsequently measured at their settiement value.
Investments in joint ventures
Investments in joint ventures are measured at cost less provision for impairment.
Fund accounting
General funds are unrestricted frjnds which are available for use at the discretion of the trustees
in furtherance of the general objectives of the Charity and which have not been designated for
other purposes.
Restricted frjnds are fijnds vthich are to be used in accordan￿ with specific restrictions imposed
by donors which have been raised by the Charity for particular purposes. The cost of raising and
administering such funds are charged against the specific fund. The aim and use of each restricted
fund is set out in the notes to the financial statements.
Judgments in applying accounting policies and key sources of estimation uncertainty
In the application of the company's accounting policies, the directors are required to make
judgements, estimates and assumptions about the carrying amount of assets and liabilities that
are not readily apparent from other sources. The estimates and associated assumptions are based
on historical experience and other factors that are considered to be relevant. Actual results may
differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to
accounting estimates are recognised in the period in which the estimate is revised where the
revision affects only that period, or in the period of the revision and future periods where the
revision affects both current and future periods.
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to
the carrying amount of assets and liabilities are as follows-
Irrecoverable debt provision
The company makes an estimate of the recoverable value of VAT from overseas countries. When
assessing the impairment of VAT recoverable, management considers factors including the ageing
profile of VAT recoverable and past experience of the recovery from the authorities involved. On
this basis, a provision was made against the balance recoverable. This provision is included within
irrecoverable debt expense.
17

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
INCOMING RESOURCES FROM CHARITABLE ACTIVITIES
Restricted Unrestricted
Funds
Funds Total Funds
2024
2024
2024
Annual congress income
Fellowships
Schools
Awards
Other activities
3,329.418
3,329.418
155,000
512
4,000
42,500
155,000
512
4,000
42.500
159.512
3.371,918
3,531.430
Restricted Unrestricted
Funds
Funds Total Funds
2023
2023
2023
Annual congress income
Fellowships
Schools
Awards
Other activities
2,844,132
2,844,132
372,000
60,000
4,000
42,500
372,000
60,000
4,000
42,500
436,000
2,886,632
3,322,632
INVESTMENT INCOME
Restricted Unrestricted Total Funds
Funds
Funds
2024
Bank interest receivable
30,521
30,521
Restricted Unrestricted Total Funds
Funds
Funds
2023
Bank interest receivable
OTHER TRADING ACTIVITIES
Restricted Unrestricted Total Funds
Funds
Funds
2024
Membership subscriptions
140,357
140,357
Restricted Unrestricted Total Funds
Funds
Funds
2023
Membership subscriptions
202,498
202,498
18

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
COSTS OF CHARITABLE ACTIVITIES BY ACTIVITY TYPE
Direct
charitable Support costs Total Funds
activities
(note 7)
2024
Grants
Education & training
Membership
Annual meetings & events
Annual congress expenditure
Newsletter & website
Society management fee
Irrecoverable debt expense
303.564
307.420
19,577
144,361
37,733
88,994
323,141
451,781
37,733
88,994
2.218,458
11,833
208,726
509,739
2.218.458
11,833
208.726
509,739
3,050,001
800,404
3,850,405
Direct grants are made up of the following=
2024
2023
Research Unit
Visiting professorship
Clinical Fellowship
Research Fellowship
Early Career Award
40,000
15.000
101,064
140,000
7,500
315,000
5,000
74,461
2,500
303,564
396,961
Direct
charitable Support costs Total Funds
activities
(note 7)
2023
Grants
Education & training
Membership
Annual meetings & events
Annual congress expenditure
Newsletter & website
Society management fee
Irrecoverable debt expense
396,961
425,032
103,728
51,264
56,333
19,389
500,689
476,296
56,333
19,389
1,920,372
14,597
237,406
30,000
1,920,372
14,597
237,406
30,000
2,994,368
260,714
3,255,082
19

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
SUPPORT COSTS
2024
2023
Office expenses
Reimbursement of salary costs
Professional consultancy fees
Foreign exchange losses
Miscellaneous
Irrecoverable debt expense
Governance costs
37,733
52,708
78,287
13,366
1,331
509,739
107,240
56,333
32,097
51,411
(147)
28,838
30,000
62,182
Note 8
800,404
260,714
GOVERNANCE COSTS
Unrestricted Total Funds Total Funds
Funds
2024
2023
Bank charges
Auditors, remuneration
Council and committee meetings
8,909
39,337
58,994
8,909
39,337
58,994
2,454
10,339
49,389
107,240
107,240
62,182
NET IOUTGOING)IINCOMING RESOURCES FOR THE YEAR
This is stated after charging=
2024
2023
Audit fees
16,754
10,339
10. STAFF COSTS AND TRANSACTIONS WITH TRUSTEES
During the year, the charitable company paid É14.539 (2023= É16.752) to 8 trustees12023= 9) for
reimbursement of travel expenses.
Reimbursement of É52,708 of salaries have been paid for work carried out on behalf of the charitsble
company during the year (2023.. É32.097).
Fees relating to ESPE Society management are included in Reimbursement of salary costs and
Professional consultsncy Fees as part of support costs- see note 7.
11. INVESTMENTS IN JOINT VENTURES
European Society for Paediatric Endocrinology ('the charitable company,) owns 50 % of the 100 £1
ordinary shares in Jointendo Limited (Registration number 15531364) incorporated in the United
Kingdom. The trading company was incorporated on 29 February 2024. The company has total
assets less current liabilities at 31 December 2024 of (£24,616) and it's trading loss for the year was
£24,737.
20

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
12. DEBTORS
2024
2023
Trade debtors
Prepayments and accrued income
Amounts due from joint ventures
VAT debtor
Other debtors
215,094
273,473
208,558
175,430
38,687
423,830
310,343
484,304
911,242
1,218,477
13. CREDITORS: Amounts falling due within one year
2024
2023
Accruals and deferred income
Other creditors
494,119
316,537
243,706
316,462
810,656
560,168
The movement on deferred income is as follows:
2024
Deferred income brought forward
Amounts released in the year
Amounts deferred in the year
15,000
{15.000)
Deferred income carried fomard
14. STATEMENT OF FUNDS
Balance at 1
January
2024
Balance at
31 December
2024
Incoming
resources
Outgoing
resources
Transfers
General
Unrestricted
Funds
5,908,446
3,542,796
13,441,854)
1213,463)
5,795,925
Restricted
Funds
Fellowships
Scholarships
Schools
Awards
other activities
155,000
(241,064
155,000)
198,987)
(13,500)
86,064
28,924
98.475
26.076
512
4,000
11.385
46.521
1,885
46,521
83,982
159,512
(408,551
213,463
48,406
TOTAL FUNDS
5,992,428
3,702,308
13.850,405)
5,844,331
21

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
14.
STATEMENT OF FUNDS (continued)
Fellowships and Scholarships
Grants allocated to young and senior members for travel and expenditure on short term or long term
clinical or scientific research projects.
Schools
Funds allocated for the organisation and housing of faculty and participants for various teaching
courses.
Awards
Funds allocated to reward somebody with a prestigious career in paediatric endocrinology or
promising students. Funds are also allocated for research projects or travel grants for young fellows.
Other activities
Funds for various activities including membership and support for the design and maintenance of the
website, and the running of webinars and other e-learning.
Transfers
Transfers from unrestricted to restricted funds are made where the expenditure on projects is not
covered by the income re￿iVed and any shortfall must be covered by the charity.
Balance at 1
January
2023
Balance at
31 December
2023
Incoming
resources
Outgoing
resources
Transfers
General
Unrestricted
Funds
5.626,857
3.090,003
(2.708.375)
(100,039)
5,908,446
Restricted
Funds
Fellowships
Scholarships
Schools
Awards
Other activities
10,389
26,076
652
11,885
46,521
372.000
(394.461)
12,072
26,076
60,000
4,000
(148,619)
(4,500)
87,967
11,385
46,521
95,523
436.000
(547.580)
100,039
83,982
TOTAL FUNDS
5.722,380
3,526.003
(3.255.955)
5,992,428
22

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
14.
STATEMENT OF FUNDS (continued)
ANALYSIS OF NET ASSETS BY FUND
Unrestricted Restricted
2024
2024
Total
2024
Investments
Net current assets
60
5,795.865
60
5.844,271
48,406
5,795.925
48,406
5,844,331
ANALYSIS OF NET ASSETS BY FUND
Unrestricted
2023
Restricted
2023
Total
2023
Net current assets
5,908.446
83,982
5,992,428
15. RELATED PAR￿ TRANSACTIONS
During the year, the charitable company incorporated a limited company joint venture Jointendo
Limited of 50 % shareholding with the charitable company European Society of Endocrinology (Charity
number 1123492). European Society for Paediatric Endocrinology paid expenditure on behalf of the
limited company totalling E208,618. At 31 December 2024, the limited company owed the European
Society of Paediatric Endocrinology É208,558, this balance is included within debtors due within one
year.
There were no other related party transactions.
16. COMPANY LIMITED BY GUARANTEE
The company is limited by guarantee and. as such, does not have a share capital. In the event of
winding up, each member has guaranteed to contribute to a maximum ofE10 to meet the liabilities of
the company.
17. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING
ACTIVITIES
2024
2023
Net movement in funds
Decreasel{increase) in debtors
Increasel(decrease) in creditors
1148,097)
307,235
250,488
270,048
(382,437}
(145,758}
Net cash used in operating activities
409,626
(258,147)
18. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM INVESTING
ACTIVITIES
2024
2023
Increase in fixed asset investments
{60)
Net cash used in operating activities
160
23

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
19. FINANCIAL INSTRUMENTS
2024
2023
Financial assets
Financial assets measured at amortised cost
5.743,685
5,334,119
Financial liabilities
Financial liabilities measured at amortised cost
810,656
545,168
Financial assets measured at amortised cost comprise cash at bank and accrued income.
Financial liabilities measured at amortised cost comprise other creditors and accruals.
24

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31 DECEMBER 2024
The following pages do not forni part of the ststutory financial ststements
which are the subject of the independentauditorfs report on pages 10 to 12.
25

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
DETAILED PROFIT AND LOSS ACCOUNT
YEAR ENDED 31 DECEMBER 2024
2024
2023
Income
Annual Congress income
Fellowships:
Clinical Fellowship
Research Fellowship
Scholarships:
Visiting Professorship
Schools-
Summer School
Winter School
Maghreb School
Caucasus & Central Asia schi)ol
Diabetes Obesity School
Science School
Awards:
Henning Andersen Prize
Other activities:
Membership
E-learning
Other
3.329.418
2,844,132
140.000
15,000
100,000
140,000
45,000.
512
4,000
4,000
140.357
42,500
202,498
102,500
87,000
Bank interest receivable
30.521
3.702.308
3,525,130
Direct costs
Annual Congress expenditure
Society management fee
Fellowships:
Clinical Fellowship
Research Unit
Research Fellowship
Scholarships:
Early Career Award
Visiting professorship
Schools:
Summer School
Winter School
Maghreb School
Science School
Caucasus and Central Asia School
Diabetes Obesity School
Webinars
ESPE Academy
Awards:
Andrea Prader Prize
Research Award
EU Outstanding Clinician
International Award
Young Investor Award
Henning Andersen Prize
Travel Grants
Undergrad Achievement Award
2,218.458
208.726
1.920,372
237,406
101.064
40,000
140,000
74,461
315,000
7.500
15.000
2,500
5,000
47.952
13,811
4.028
68,771
13,325
37,310
35,000
15,571
2,763
4,834
20,500
20.006
27.362
5.439
17.500
7.500
5,000
7,500
5,000
3,500
5.000
5.000
6.000
11,839
2.250
5,000
2,000
34,000
750
2.909.435
2.810,563
Gross surplus carried forward
792,873
714,567
26

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
DETAILED PROFIT AND LOSS ACCOUNT
YEAR ENDED 31 DECEMBER 2024
2024
2023
Gross surplus brought forward
792,873
714,567
Other activities:
Printing and publishing
Website costs
Marketing and communication
Miscellaneous
31.537
100.976
8.053
1.331
72,716
104,377
6,712
28,838
Gross surplus
650.976
501,924
Governance costs:
Bank charges
Council and committee meetings
Auditors remuneration
Support costs:
Office expenses
Legal fees
Reimbursement of salary costs
Professional consultancy fees
Repairs and maintenance
Irrecoverable debt expense
8,909
58.994
39.337
2,454
49.389
10,339
37.733
56.333
52.708
78.287
32.097
51,411
509.739
30,000
785,707
232,023
Operating Ideficit)Isurplus
(134,731)
269,901
Foreign currency {losses)Igains
IDeficit)Isurplus on ordinary activities
113.366)
147
(148,097)
270,048
27